|
US4737462A
(en)
|
1982-10-19 |
1988-04-12 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
GB9325182D0
(en)
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
|
JP4046349B2
(ja)
|
1994-11-07 |
2008-02-13 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
腫瘍壊死因子−γ
|
|
US20030198640A1
(en)
|
1994-11-07 |
2003-10-23 |
Human Genome Sciences, Inc. |
Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
|
|
US6599719B2
(en)
|
1994-11-07 |
2003-07-29 |
Human Genome Sciences, Inc. |
Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
|
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US20030129189A1
(en)
|
1994-11-07 |
2003-07-10 |
Guo-Liang Yu |
Tumor necrosis factor-gamma
|
|
US7597886B2
(en)
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US6824767B2
(en)
|
1994-11-07 |
2004-11-30 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
EP0859841B1
(en)
|
1995-08-18 |
2002-06-19 |
MorphoSys AG |
Protein/(poly)peptide libraries
|
|
US6828422B1
(en)
|
1995-08-18 |
2004-12-07 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
|
US6632976B1
(en)
|
1995-08-29 |
2003-10-14 |
Kirin Beer Kabushiki Kaisha |
Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
|
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
|
WO1999029888A1
(en)
|
1997-12-05 |
1999-06-17 |
The Scripps Research Institute |
Humanization of murine antibody
|
|
US6297367B1
(en)
|
1997-12-30 |
2001-10-02 |
Chiron Corporation |
Polynucleotide encoding TNFL1
|
|
WO1999045959A1
(en)
|
1998-03-13 |
1999-09-16 |
Dana-Farber Cancer Institute, Inc. |
Humanized antibody and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
AU5124500A
(en)
|
1999-04-30 |
2000-11-17 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
ATE482275T1
(de)
|
1999-07-02 |
2010-10-15 |
Morphosys Ag |
Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
|
|
US6399857B1
(en)
|
1999-09-22 |
2002-06-04 |
Paradigm Genetics, Inc. |
Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
|
|
US20110131679A2
(en)
|
2000-04-19 |
2011-06-02 |
Thomas La Rosa |
Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
|
|
US6571638B2
(en)
|
2000-06-30 |
2003-06-03 |
Sawtek, Inc. |
Surface-acoustic-wave pressure sensor and associated methods
|
|
AU2001277857A1
(en)
|
2000-07-07 |
2002-01-21 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US6824989B1
(en)
|
2000-09-01 |
2004-11-30 |
Upstate Biotechnology, Inc. |
Recombinant monoclonal antibody to phosphotyrosine-containing proteins
|
|
US20030017518A1
(en)
|
2001-06-26 |
2003-01-23 |
Joseph Lam |
Non-radio-active assay of LPS kinases
|
|
CA2476166C
(en)
|
2002-02-14 |
2011-11-15 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US7314974B2
(en)
|
2002-02-21 |
2008-01-01 |
Monsanto Technology, Llc |
Expression of microbial proteins in plants for production of plants with improved properties
|
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
DK1551876T3
(da)
|
2002-10-16 |
2011-06-14 |
Purdue Pharma Lp |
Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
|
|
CA2507080C
(en)
|
2002-11-27 |
2015-01-06 |
Biogen Idec Ma Inc. |
Humanized antibodies against monocyte chemotactic proteins
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20050101889A1
(en)
|
2003-11-06 |
2005-05-12 |
Freeman Gary A. |
Using chest velocity to process physiological signals to remove chest compression artifacts
|
|
JP2008505645A
(ja)
|
2004-07-10 |
2008-02-28 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
CN101198624B
(zh)
|
2005-05-06 |
2012-10-10 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
|
WO2006122187A2
(en)
|
2005-05-10 |
2006-11-16 |
Biogen Idec Ma Inc. |
Treating and evaluating inflammatory disorders
|
|
US20090317388A1
(en)
|
2005-05-25 |
2009-12-24 |
Linda Burkly |
Tl1a in treatment of disease
|
|
CN103145837A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
DK1919954T3
(en)
|
2005-08-30 |
2017-01-30 |
Univ Miami |
Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
US7691980B2
(en)
|
2007-01-09 |
2010-04-06 |
Bio-Rad Laboratories, Inc. |
Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
|
|
US20110217310A1
(en)
|
2007-01-10 |
2011-09-08 |
Siegel Richard M |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
|
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
|
US20100055700A1
(en)
|
2007-02-28 |
2010-03-04 |
Cedars-Sinai Medical Center |
Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
|
|
MX2010005282A
(es)
|
2007-11-13 |
2010-08-31 |
Teva Pharma |
Anticuerpos humanizados contra tl1a.
|
|
CN101469270B
(zh)
|
2007-12-27 |
2012-08-22 |
牛斌 |
工业连续化塑料裂解器
|
|
US8093364B2
(en)
|
2008-01-18 |
2012-01-10 |
Bio-Rad Laboratories, Inc. |
Enhanced purification of antibodies and antibody fragments by apatite chromatography
|
|
US20090226435A1
(en)
|
2008-03-08 |
2009-09-10 |
Sanjay Khare |
Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
|
|
CA2737636A1
(en)
|
2008-09-29 |
2010-04-01 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
|
US9221902B2
(en)
*
|
2008-11-07 |
2015-12-29 |
Fabrus, Inc. |
Combinatorial antibody libraries and uses thereof
|
|
WO2010111180A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
ES2586837T3
(es)
|
2009-08-03 |
2016-10-19 |
University Of Miami |
Método para la expansión in vivo de linfocitos T reguladores
|
|
WO2011106707A2
(en)
|
2010-02-26 |
2011-09-01 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to dr3
|
|
KR101603001B1
(ko)
|
2010-08-25 |
2016-03-11 |
에프. 호프만-라 로슈 아게 |
Il-18r1에 대한 항체 및 그의 용도
|
|
KR101871008B1
(ko)
|
2010-09-16 |
2018-06-25 |
발리오팜 아게 |
항-huTNFR1 항체
|
|
US8766034B2
(en)
|
2010-09-22 |
2014-07-01 |
Cedars-Sinai Medical Center |
TL1A model of inflammation fibrosis and autoimmunity
|
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
US9902996B2
(en)
|
2011-02-11 |
2018-02-27 |
Cedars-Sinai Medical Center |
Methods of predicting the need for surgery in crohn's disease
|
|
AU2012259312A1
(en)
|
2011-05-20 |
2013-12-12 |
Government Of The United States, As Represented By The Secretary Department Of Health And Human Services |
Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
|
|
EP2714735B1
(en)
|
2011-06-03 |
2021-07-21 |
XOMA Technology Ltd. |
Antibodies specific for tgf-beta
|
|
WO2013002362A1
(ja)
|
2011-06-30 |
2013-01-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
EP3495389A1
(en)
|
2011-09-30 |
2019-06-12 |
Teva Pharmaceuticals Australia Pty Ltd |
Antibodies against tl1a and uses thereof
|
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
EP2660325A3
(en)
|
2012-05-02 |
2014-02-12 |
Christian Medical College |
AAV vectors and corresponding nucleotide sequences and methods
|
|
CA2876096A1
(en)
|
2012-08-02 |
2014-02-06 |
Petra Rueger |
Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
|
|
SG11201408530YA
(en)
|
2012-08-02 |
2015-03-30 |
Hoffmann La Roche |
Method for producing monomeric and multimeric molecules and uses thereof
|
|
JPWO2014051109A1
(ja)
|
2012-09-28 |
2016-08-25 |
協和発酵キリン株式会社 |
抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
|
WO2014106602A1
(en)
|
2013-01-02 |
2014-07-10 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to tl1a and their uses
|
|
EP4421177A3
(en)
|
2013-03-13 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Prefusion rsv f proteins and their use
|
|
ES2699599T3
(es)
|
2013-03-15 |
2019-02-11 |
Abbvie Biotherapeutics Inc |
Variantes de Fc
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
EP3022295A4
(en)
|
2013-07-19 |
2017-03-01 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
CN105814081B
(zh)
|
2013-11-13 |
2021-02-02 |
辉瑞大药厂 |
肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
|
|
ES2811274T3
(es)
|
2014-04-18 |
2021-03-11 |
Univ Leland Stanford Junior |
Anticuerpos monoclonales humanizados y quiméricos para CD99
|
|
EP3137063A4
(en)
|
2014-05-02 |
2017-12-13 |
Teva Pharmaceutical Industries Ltd. |
Treatment of crohn's disease with delayed-release 6-mercaptopurine
|
|
WO2015173756A2
(en)
|
2014-05-16 |
2015-11-19 |
Pfizer Inc. |
Bispecific antibodies
|
|
US10160805B2
(en)
|
2014-07-11 |
2018-12-25 |
New York University |
Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
|
|
ES2788979T3
(es)
|
2014-11-14 |
2020-10-23 |
Hoffmann La Roche |
Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
JP6996979B2
(ja)
|
2015-03-31 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
三量体ｔｎｆファミリーリガンドを含む抗原結合分子
|
|
EP3280439A1
(en)
|
2015-04-07 |
2018-02-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Anti-pd-l1 immunotoxin for use in therapy
|
|
US10647756B2
(en)
*
|
2015-05-18 |
2020-05-12 |
Pfizer Inc. |
Humanized antibodies
|
|
JP6932700B2
(ja)
|
2015-09-15 |
2021-09-08 |
アムジエン・インコーポレーテツド |
４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
MY206406A
(en)
|
2015-10-02 |
2024-12-16 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
US20180319889A1
(en)
|
2015-11-02 |
2018-11-08 |
La Jolla Institute For Allergy & Immunology |
Method and medicament for treating airway and/or lung diseases
|
|
ITUB20155097A1
(it)
|
2015-11-05 |
2017-05-05 |
Biouniversa Srl |
Anticorpi umanizzati anti-BAG3
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
KR102527840B1
(ko)
|
2016-04-29 |
2023-05-03 |
화이자 인코포레이티드 |
인터페론 베타 항체 및 그의 용도
|
|
US10968279B2
(en)
|
2016-05-09 |
2021-04-06 |
Bristol-Myers Squibb Company |
TL1A antibodies and uses thereof
|
|
WO2018022628A1
(en)
|
2016-07-25 |
2018-02-01 |
Cephalon, Inc. |
Affinity chromatography wash buffer
|
|
MY191324A
(en)
*
|
2016-10-26 |
2022-06-15 |
Cedars Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
|
AU2017378393B2
(en)
|
2016-12-14 |
2023-03-09 |
Bt Bidco, Inc. |
Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
|
|
US10626180B2
(en)
*
|
2017-04-20 |
2020-04-21 |
Cedars-Sinai Medical Center |
Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
|
|
CN111788225B
(zh)
|
2017-10-10 |
2025-02-18 |
赛诺菲 |
抗cd38抗体及与抗cd3和抗cd28抗体的组合
|
|
CA3086098A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
CN119735681A
(zh)
|
2018-04-25 |
2025-04-01 |
普罗米修斯生物科学公司 |
优化的抗tl1a抗体
|
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
TWI856979B
(zh)
|
2018-10-09 |
2024-10-01 |
法商賽諾菲公司 |
三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
|
|
KR20210080460A
(ko)
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
이종이량체성 Fc-융합된 단백질
|
|
TW202600603A
(zh)
|
2019-10-24 |
2026-01-01 |
美商普羅米修斯生物科學股份有限公司 |
針對類-tnf配體1a (tl1a)之人類化抗體及其用途
|
|
EP4171632A2
(en)
|
2020-06-26 |
2023-05-03 |
Pfizer Inc. |
Methods of treating inflammatory bowel disease with tl1a antibodies
|
|
KR20230158494A
(ko)
|
2021-02-18 |
2023-11-20 |
프로메테우스 바이오사이언시즈, 인크. |
항-tl1a 항체 조성물 및 폐에서의 치료 방법
|
|
GEAP202416596A
(en)
|
2021-02-18 |
2024-10-28 |
Cedars Sinai Medical Center |
Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
|